Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2018
  • Article
  • Clinical Pharmacology & Therapeutics

Innovation Incentives and Biomarkers

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
  • Format:Print
ShareBar

Abstract

Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis and prognosis, predict treatment efficacy or toxicity, serve as markers of disease progression, and serve as auxiliary endpoints for clinical trials. Some have multiple uses, while others have a specialized role, resulting in diverse incentives across players in the healthcare system.

Keywords

Health Care and Treatment; Innovation and Invention; Research and Development; Markets

Citation

Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "Innovation Incentives and Biomarkers." Clinical Pharmacology & Therapeutics 103, no. 1 (January 2018): 34–36.
  • Find it at Harvard
  • Purchase

About The Authors

Ariel D. Stern

Technology and Operations Management
→More Publications

Amitabh Chandra

Technology and Operations Management
→More Publications

More from the Authors

    • August 2022
    • JAMA Internal Medicine

    Trends in Remote Patient Monitoring Use in Traditional Medicare

    By: Mitchell Tang, Carter Nakamoto, Ariel Dora Stern and Ateev Mehrotra
    • July 2022
    • Faculty Research

    Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)

    By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
    • Harvard Business Manager

    Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry]

    By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
More from the Authors
  • Trends in Remote Patient Monitoring Use in Traditional Medicare By: Mitchell Tang, Carter Nakamoto, Ariel Dora Stern and Ateev Mehrotra
  • Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement) By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
  • Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry] By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College